Elsevier

Brain Stimulation

Volume 10, Issue 3, May–June 2017, Pages 664-671
Brain Stimulation

Deep brain stimulation to the medial forebrain bundle for depression- long-term outcomes and a novel data analysis strategy

https://doi.org/10.1016/j.brs.2017.01.581Get rights and content

Highlights

  • Deep brain stimulation (DBS) of the medial forebrain bundle in treatment-resistant depression led to antidepressant effects.

  • Antidepressant effects were rapid and sustained for up to four years in a small sample.

  • Timeline analysis could reflect more adequately patient's overall gain throughout the study than endpoint-analyses.

  • Study design (endpoint selection, response, placebo, outcome measure) in DBS for treatment-resistant depression is discussed.

Abstract

Background

Deep brain stimulation (DBS) of the supero-lateral branch of the medial forebrain bundle (slMFB) in treatment-resistant depression (TRD) is associated with acute antidepressant effects.

Objective

Long-term clinical effects including changes in quality of life, side effects and cognition as well as long-term data covering four years are assessed.

Methods

Eight TRD patients were treated with DBS bilateral to the slMFB. Primary outcome measure was a 50% reduction in Montgomery-Åsberg Depression Rating Scale (MADRS) (response) and remission (MADRS <10) at 12 months compared to baseline. Secondary measures were anxiety, general functioning, quality of life, safety and cognition assessed for 4 years. Data is reported as conventional endpoint-analysis and as area under the curve (AUC) timeline analysis.

Results

Six of eight patients (75%) were responders at 12 months, four patients reached remission. Long-term results revealed a stable effect up to four years. Antidepressant efficacy was also reflected in the global assessment of functioning. Main side effect was strabismus at higher stimulation currents. No change in cognition was identified. AUC analysis revealed a significant reduction in depression for 7/8 patients in most months.

Conclusions

Long-term results of slMFB-DBS suggest acute and sustained antidepressant effect; timeline analysis may be an alternative method reflecting patient's overall gain throughout the study. Being able to induce a rapid and robust antidepressant effect even in a small, sample of TRD patients without significant psychiatric comorbidity, render the slMFB an attractive target for future studies.

Introduction

About 30% of patients suffering from major depressive disorder (MDD) fail to respond to established pharmacological, psychotherapeutic or somatic treatments [1] and are then classified as having a treatment-resistant depression (TRD). Deep brain stimulation (DBS) at different brain targets is currently under research as a possible treatment option for TRD. In small pilot studies, antidepressant effects of DBS at the subgenual cingulate gyrus (Cg25) [2], [3], [4], the anterior limb of the capsula interna (ALIC) [5], [6] and the nucleus accumbens (Nacc) [7], [8] are described. A significant response, defined as a reduction of symptoms over 50%, was reached in about 50% of the patients after 12 months of DBS treatment [6], [9], [10], [11], [12], [13]. First larger clinical trials including a placebo phase stimulating ALIC [14] or Cg25 [15] failed to prove efficacy underlining the importance of a careful analysis of pilot studies to optimize the study design in randomized-controlled studies (for a detailed comment see Ref. [16]). Recently, DBS at the supero-lateral branch of the medial forebrain bundle (slMFB) was presented as a new DBS target. A more rapid antidepressant response in seven patients of the present sample with a response rate of 85% after three months DBS was obtained in an interim analysis [17] (for a detailed description of mode of action see Refs. [18], [19], [20]). Long-term data on this target are lacking.

Traditionally, data in depression studies on patients that are not resistant to treatment is reported at predefined study end points, mostly six to twelve weeks, due to the assumed latency of clinical response to pharmacotherapy [21]. In the TRD population, different ways of data analysis are suggested [22], [23]. Patients suffering from TRD cannot be cured –in the sense of a stable absence of symptoms-within short intervals and response to any treatment approach varies during the process of the study. Assessing at fixed, somewhat arbitrarily chosen end points might be misleading [23] and cannot convey all information about the impact of the treatment [24]. From the patient's as well as from the clinician's perspective, the benefit from a treatment is the degree of improvement over time. Therefore, we have analyzed our 12 months data both in the conventional way as well as in a timeline analysis. Timeline analyses are standard in other fields such as endocrinology [25], cardiology [26] and diabetes research [27]. A symptom reduction of 50% from baseline is conventionally used as response criterion. We propose a larger differentiation of this arbitrarily chosen criterion for the population of TRD (see Refs. [10], [28], for a detailed discussion of the response criterion, [29]).

In this study, antidepressant effects of DBS to the slMFB for up to four years are described. Anxiety, social functioning, quality of life, safety and cognition are reported at fixed time points and with timeline data analysis.

Section snippets

Patients

Three-month follow-up data of seven patients have recently been published [30]. One further patient has been included in this study because we had a raise in funding, he received the same protocol; so eight patients received slMFB DBS for 48 months. All patients suffered at baseline from severe treatment-resistant depression according to DSM-IV [SCID-I & II] [31]. One bipolar patient was included in this study (last manic episode occurred 23 years ago). Three raters analyzed clinical records.

Demographic and clinical characteristics

Eight patients between 30 and 55 years of age with a current depressive episode of 7.1 ± 4.48 years were included in this study (see Table 1 for demographic and clinical details). All patients were diagnosed having severe TRD with an ATHF score of 3 in the current episode. A score of “3” is the threshold for considering a trial adequate and the patient resistant to that treatment. Before DBS implantation, patients were treated with 18.8 ± 7.03 antidepressant medications, had received ECT and

Antidepressant efficacy - conventional analysis

Long-term antidepressant effects following bilateral supero-lateral branch of the medial forebrain bundle (slMFB)-DBS in patients suffering from severe TRD have been demonstrated in this study. 75% of the patients responded to the slMFB-DBS at twelve months. There was a significant reduction in depression score in each month compared to the baseline in all depression scales (see Ref. [45] for a meta-analysis of the correlation of different measures of depression in long-term studies). The

Conclusions

The slMFB appears to be a promising target for DBS in TRD. The strong antidepressant effect was sustained up to four years with few side effects and could be detected in a small sample. Traditionally, placebo-controlled comparison-group trials are the gold standard in clinical studies. For TRD-DBS, a high-risk interventional treatment for chronically ill patients, study designs have to be carefully balanced with ethical criteria, especially in the light of the failure of the two large

Acknowledgment and conflict of interest

This investigator-initiated study was funded in part (DBS device, battery exchange, medical costs, and limited support for study nurse) by a grant of Medtronic. to Dr. Schlaepfer and Dr. Coenen. All other authors state no conflict of interest. The sponsor had no influence on design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.

We especially thank Dr. Ali Sarem-Aslani, Medtronic Inc. for his many

References (57)

  • J.C. Pruessner et al.

    Two formulas for computation of the area under the curve represent measures of total hormone concentration versus time-dependent change

    Psychoneuroendocrinology

    (2003)
  • Z. Bukumiric et al.

    Meta-analysis of the changes in correlations between depression instruments used in longitudinal studies

    J Affect Disord

    (2016)
  • A.J. Fenoy et al.

    Deep brain stimulation of the medial forebrain bundle: Distinctive responses in resistant depression

    J Affect Disord

    (2016)
  • A.F. Schatzberg et al.

    Use of placebo control groups in evaluating efficacy of treatment of unipolar major depression

    Biol Psychiatry

    (2000)
  • P.A. Nakonezny et al.

    Predicting placebo response in adolescents with major depressive disorder: the Adolescent Placebo Impact Composite Score (APICS)

    J Psychiatr Res

    (2015)
  • F.K. Vergunst et al.

    Longitudinal course of symptom severity and fluctuation in patients with treatment-resistant unipolar and bipolar depression

    Psychiatry Res

    (2013)
  • V.A. Coenen et al.

    Cross-species affective functions of the medial forebrain bundle-Implications for the treatment of affective pain and depression in humans

    Neurosci Biobehav Rev

    (2011 Oct)
  • A.J. Rush et al.

    Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report

    Am J Psychiatry

    (2006)
  • H.E. McNeely et al.

    Neuropsychological impact of Cg25 deep brain stimulation for treatment-resistant depression: preliminary results over 12 months

    J Nerv Ment Dis

    (2008)
  • D.A. Malone

    Use of deep brain stimulation in treatment-resistant depression

    Clevel Clin J Med

    (2011)
  • T.E. Schlaepfer et al.

    Deep brain stimulation to reward circuitry alleviates anhedonia in refractory major depression. Neuropsychopharmacology

    official Publ Am Coll Neuropsychopharmacol

    (2008)
  • B.H. Bewernick et al.

    Long-term effects of nucleus accumbens deep brain stimulation in treatment-resistant depression: evidence for sustained efficacy

    Neuropsychopharmacology

    (2012)
  • A.M. Lozano et al.

    A multicenter pilot study of subcallosal cingulate area deep brain stimulation for treatment-resistant depression

    J Neurosurg

    (2012)
  • D. Puigdemont et al.

    Deep brain stimulation of the subcallosal cingulate gyrus: further evidence in treatment-resistant major depression

    Int J Neuropsychopharmacol

    (2012)
  • S.H. Kennedy et al.

    Deep brain stimulation for treatment-resistant depression: follow-up after 3 to 6 years

    Am J Psychiatry

    (2011)
  • P.E. Holtzheimer et al.

    Subcallosal cingulate deep brain stimulation for treatment-resistant unipolar and bipolar depression

    Arch Gen Psychiatry

    (2012)
  • D. Dougherty et al.

    720-A randomized sham-Controlled trial of DBS of the VC/VS for treatment-resistant depression

    Biol Psychiatry

    (2012)
  • V.A. Coenen et al.

    Individual fiber anatomy of the subthalamic region revealed with diffusion tensor imaging: a concept to identify the deep brain stimulation target for tremor suppression

    Neurosurgery

    (2011)
  • Cited by (111)

    View all citing articles on Scopus
    View full text